Join a 6-month remote study exploring how oral semaglutide (Wegovy®) affects metabolic and inflammatory health markers in adults prescribed the medication through the Hims & Hers telehealth platform. Your participation helps build real-world evidence on how this treatment works in everyday life — entirely from your home. Participation is limited to patients who are currently prescribed oral semaglutide through the Hims & Hers platform.
Participation is fully remote and takes place through the Alethios app. You’ll complete short surveys about your weight, energy, appetite, and how you’re feeling at three timepoints over 6 months. Monthly check-ins keep things on track and give you a chance to report anything important.
Complete a short screening questionnaire to confirm you qualify. If eligible, review the study details and sign your electronic consent form through the Alethios platform.
Complete your baseline demographics, medical history, and initial questionnaires through the Alethios app. Confirm receipt of your GLP-1 on the platform as soon as you receive it.
Each month, complete brief check-ins about your weight, energy, appetite, and medication adherence.
At Month 6, complete your final surveys and at-home blood collection. Adherent participants will receive up to $150 in Amazon gift cards — $50 at baseline, $50 at Month 3, and $50 at Month 6.
This study is examining how oral semaglutide (Wegovy®) — a pill prescribed for weight management — affects key metabolic and inflammatory markers in real-world patients. While clinical trials have shown that semaglutide helps with weight loss, less is known about how it affects things like blood sugar, cholesterol, inflammation, and liver function when prescribed through a telehealth platform. This study tracks those changes over 6 months using at-home blood testing and regular check-in surveys.
.svg)
